{"product_id":"radiation-without-surgery-how-sbrt-is-changing-treatment-for-breast-cancer-liver-metastases","title":"Radiation Without Surgery: How SBRT Is Changing Treatment for Breast Cancer Liver Metastases","description":"\u003cp\u003eBreast cancer that spreads to the liver has historically carried a poor outlook, with survival measured in months, but a precise, non-invasive radiation technique called stereotactic body radiotherapy (SBRT) is emerging as a safe and effective alternative to surgery for selected patients. This review from the University of Tokyo Hospital examined published studies on SBRT for liver metastases, finding that breast cancer origin is actually a favorable prognostic factor and that 1-year local control rates range from 70% to 100%, with 2-year rates from 60% to 90%. The research shows that SBRT offers excellent tumor control with minimal toxicity — serious side effects occur in less than 5% of patients — making it a promising option for patients who cannot undergo surgery or ablation. While patient selection criteria and optimal dosing are still being refined, the evidence supports SBRT as a feasible, safe, and potentially curative treatment for breast cancer liver metastases.\u003c\/p\u003e\n\n\u003ch1\u003eRadiation Without Surgery: How SBRT Is Changing Treatment for Breast Cancer Liver Metastases\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eUnderstanding the Problem: Breast Cancer Liver Metastases\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#local-treatment\"\u003eThe Rise of Local Treatments for Oligometastases\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#surgery\"\u003eSurgery: The Traditional First Choice — and Its Limits\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#other-modalities\"\u003eOther Local Treatment Options and Their Drawbacks\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#what-is-sbrt\"\u003eWhat Exactly Is SBRT?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#eligibility\"\u003eWho Can Receive SBRT for Liver Metastases?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#procedure\"\u003eHow SBRT Is Delivered: The Treatment Procedure\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#dose\"\u003eRadiation Doses Used in SBRT\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#constraints\"\u003eProtecting Healthy Organs: Dose Constraints\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#concomitant\"\u003eCombining SBRT with Systemic Therapy\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#results\"\u003eTreatment Results: What Studies Show\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#predictors\"\u003ePredictors of Success: Who Benefits Most?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#toxicity\"\u003eSide Effects and Toxicity: How Safe Is SBRT?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#rild\"\u003eRadiation-Induced Liver Disease: A Key Concern\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#conclusions\"\u003eConclusions: Where SBRT Stands Today\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of the Current Evidence\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eSBRT delivers precise, high-dose radiation to breast cancer liver metastases in 1–6 sessions, sparing healthy liver.\u003c\/li\u003e\n\u003cli\u003eIn studies, 1-year local control ranges from 70% to 100%; serious side effects occur in under 5%.\u003c\/li\u003e\n\u003cli\u003eBreast cancer origin is a favorable prognostic factor for liver SBRT, with excellent control and survival in trials.\u003c\/li\u003e\n\u003cli\u003eEligibility typically includes up to 5 metastases each ≤6 cm, Child-Pugh A, and adequate healthy liver volume.\u003c\/li\u003e\n\u003cli\u003eSBRT complements systemic therapy; no increased side effects have been reported when combining treatments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eUnderstanding the Problem: Breast Cancer Liver Metastases\u003c\/h2\u003e\n\n\u003cp\u003eThe liver is one of the most common sites where solid tumors — including breast cancer — spread. When breast cancer cells travel to the liver, the condition is called breast cancer liver metastasis (BCLM), and it represents a challenging clinical scenario. The numbers are sobering: liver metastases develop in \u003cstrong\u003eapproximately 50% of all patients with metastatic breast cancer\u003c\/strong\u003e, and in 5–12% of patients, the liver is the primary (first) site of breast cancer recurrence.\u003c\/p\u003e\n\n\u003cp\u003eThe prognosis for BCLM has historically been poor. Without any treatment, survival is just 4–8 months. Even with modern systemic therapies such as chemotherapy and hormone therapy, the average survival extends to only \u003cstrong\u003e18–24 months\u003c\/strong\u003e. These figures underscore why researchers have been searching for better ways to control disease in the liver and improve long-term outcomes.\u003c\/p\u003e\n\n\u003ch2 id=\"local-treatment\"\u003eThe Rise of Local Treatments for Oligometastases\u003c\/h2\u003e\n\n\u003cp\u003eFor decades, the standard approach to advanced breast cancer was systemic therapy — hormone therapy and\/or chemotherapy given with the goal of palliation (relieving symptoms and extending life) rather than cure. Local treatments like surgery or radiation were used infrequently.\u003c\/p\u003e\n\n\u003cp\u003eThat thinking has changed dramatically. A concept called \u003cstrong\u003e\"oligometastases\"\u003c\/strong\u003e — meaning a limited number of metastatic spots (typically five or fewer) — has gained widespread acceptance. The idea is that when cancer has spread to only a few locations, aggressively treating those spots with curative intent could improve disease control and overall survival. This has opened the door for local therapies, including radiation, to play a meaningful role in metastatic breast cancer care.\u003c\/p\u003e\n\n\u003ch2 id=\"surgery\"\u003eSurgery: The Traditional First Choice — and Its Limits\u003c\/h2\u003e\n\n\u003cp\u003eSurgical resection (removing the tumor) has been the first-choice local treatment for patients with a limited number of liver metastases from various primary cancers. For those who undergo complete surgical removal, the results can be impressive: reported \u003cstrong\u003e5-year survival rates range from 30% to 58%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eHowever, surgery has a significant limitation: only \u003cstrong\u003e10–30% of patients with liver metastases are eligible for resection\u003c\/strong\u003e. The reasons are both medical and technical — the number or location of tumors may make surgery unsafe, or the patient may not be healthy enough to withstand an operation. This leaves the majority of patients in need of alternative local treatment options.\u003c\/p\u003e\n\n\u003ch2 id=\"other-modalities\"\u003eOther Local Treatment Options and Their Drawbacks\u003c\/h2\u003e\n\n\u003cp\u003eTo serve patients who are not surgical candidates, several other local ablative (tissue-destroying) techniques have been tried. These include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eRadiofrequency ablation (RFA) — using heat to destroy tumors\u003c\/li\u003e\n  \u003cli\u003eTranscatheter arterial chemoembolization (TACE) — delivering chemotherapy directly to the liver tumor through a catheter\u003c\/li\u003e\n  \u003cli\u003eCryotherapy — freezing tumors\u003c\/li\u003e\n  \u003cli\u003eRadioembolization (Y90) — delivering radioactive beads to tumors via the bloodstream\u003c\/li\u003e\n  \u003cli\u003eThermal ablation\u003c\/li\u003e\n  \u003cli\u003eRadiotherapy (RT)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAmong these, RFA has been the most widely used ablation technique. But RFA has real limitations. It works best for lesions that are ≤3 cm in size — larger tumors are harder to completely destroy. Lesions located near major blood vessels or under the liver capsule (the outer lining) are also problematic. Perhaps most concerning, \u003cstrong\u003elocal recurrence after RFA is relatively high — up to 40% of patients\u003c\/strong\u003e — especially when tumors are located close to the liver hilum (the area where blood vessels and bile ducts enter the liver).\u003c\/p\u003e\n\n\u003ch2 id=\"what-is-sbrt\"\u003eWhat Exactly Is SBRT?\u003c\/h2\u003e\n\n\u003cp\u003eHistorically, radiation therapy played only a limited role in liver tumors. The liver is highly sensitive to radiation, and it was thought to be nearly impossible to deliver the high doses needed to destroy metastatic tumors without severely damaging healthy liver tissue.\u003c\/p\u003e\n\n\u003cp\u003eTechnological advances changed this. \u003cstrong\u003eStereotactic body radiation therapy (SBRT)\u003c\/strong\u003e is a technique that delivers a very conformal (precisely shaped) radiation dose to the tumor while giving only minimal radiation to the surrounding healthy liver. This allows normal liver tissue to be spared.\u003c\/p\u003e\n\n\u003cp\u003eSBRT delivers high-dose radiation to the tumor in a small number of sessions — typically \u003cstrong\u003e1 to 6 fractions\u003c\/strong\u003e — in contrast to conventional radiation therapy, which uses low doses per treatment (usually 1.5–3 Gy) delivered to a larger volume over many weeks. SBRT is non-invasive, which makes it an attractive option for patients with liver oligometastases who are not eligible for surgery, RFA, or liver transplantation.\u003c\/p\u003e\n\n\u003cp\u003eThe growing body of research on liver SBRT — both prospective and retrospective — has shown encouraging results in terms of local control (keeping the treated tumor from growing back), toxicity (side effects), and overall survival.\u003c\/p\u003e\n\n\u003ch2 id=\"eligibility\"\u003eWho Can Receive SBRT for Liver Metastases?\u003c\/h2\u003e\n\n\u003cp\u003eOne of the advantages of SBRT over surgery is that it is less constrained by the location of tumors within the liver. Most clinical trials have defined SBRT as an alternative therapy or a salvage (rescue) therapy for inoperable or post-operative isolated liver metastases.\u003c\/p\u003e\n\n\u003cp\u003eThe most frequently used eligibility criteria in studies include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003eFewer than or equal to 5 liver metastases\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eMaximum tumor size of 6 cm\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eControlled or absent extra-hepatic disease\u003c\/strong\u003e (cancer outside the liver is under control or does not exist)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGood performance status\u003c\/strong\u003e — meaning the patient is generally well-functioning (Eastern Cooperative Oncology Group [ECOG] score 0–1, or Karnofsky score \u0026gt;70)\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eAdequate hepatic volume and liver function\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eLiver function has been defined in various ways across studies. Scorsetti and colleagues published a treatment algorithm that used two key indicators:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eThe \u003cstrong\u003eChild-Pugh score\u003c\/strong\u003e (A, B, or C — a standard measure of liver disease severity)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e\"Free liver volume\"\u003c\/strong\u003e — the amount of healthy liver that can be spared from radiation (\u0026gt;1,000 mL or \u0026lt;1,000 mL, and ≥700 mL or \u0026lt;700 mL)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eChildren-Pugh class A and a free liver volume greater than 1,000 mL were recommended as good indications for liver SBRT. To prevent side effects, the authors also required that tumors be located \u003cstrong\u003emore than 8 mm away from other organs at risk\u003c\/strong\u003e (like the stomach or bowel). Interestingly, age was not included in selection criteria in almost all studies. In fact, this is precisely why SBRT is often chosen for elderly patients — many of whom are not suitable candidates for surgery.\u003c\/p\u003e\n\n\u003ch2 id=\"procedure\"\u003eHow SBRT Is Delivered: The Treatment Procedure\u003c\/h2\u003e\n\n\u003cp\u003eLiver SBRT is technically challenging, primarily because of \u003cstrong\u003erespiration-related organ motion\u003c\/strong\u003e — the liver moves as the patient breathes. Delivering precise radiation requires highly accurate dose planning, typically using multiple radiation beams arranged in coplanar (same plane) or non-coplanar (multiple planes) geometries.\u003c\/p\u003e\n\n\u003cp\u003eModern technology has made this easier. Intensity-modulated radiation therapy (IMRT), and more recently \u003cstrong\u003evolumetric arc radiation therapy (VMAT)\u003c\/strong\u003e and the \u003cstrong\u003eframeless robotic radiosurgery system (CyberKnife®)\u003c\/strong\u003e, achieve dose distributions that closely fit the shape of the target while reducing exposure to other organs.\u003c\/p\u003e\n\n\u003cp\u003eTo account for respiratory movement, several processes are added to treatment planning:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePlanning CT scans\u003c\/strong\u003e should be obtained at least above and below the region of interest, during both expiration and inspiration, in addition to free breathing. More recently, it has become recommended that \u003cstrong\u003efour-dimensional CT (4D-CT)\u003c\/strong\u003e simulations be performed — this imaging technique tracks tumor movement throughout the breathing cycle to more accurately define the target.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMRI fusion\u003c\/strong\u003e — Since the liver is a solid organ, it is required to fuse magnetic resonance imaging (MRI) and\/or 18-fluorodeoxyglucose positron emission tomography (FDG-PET)-CT with contrast-enhanced CT for precise targeting.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eImage-guided radiation therapy (IGRT)\u003c\/strong\u003e — This is performed before each daily treatment session to reduce positioning errors. In selected patients, tiny fiducial markers (small gold seeds) are implanted in or near the tumor to help with target localization.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eBeyond imaging, there are techniques that reduce respiratory movement itself:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eOxygen inhalation\u003c\/li\u003e\n  \u003cli\u003eAbdominal compression\u003c\/li\u003e\n  \u003cli\u003eRespiratory arrest (breath-holding restriction)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn combination with these, two techniques reduce the influence of respiratory movement: \u003cstrong\u003erespiratory synchronization\u003c\/strong\u003e (delivering radiation at a specific point in the breathing cycle) and \u003cstrong\u003emoving-body tracking\u003c\/strong\u003e (the radiation beam follows the tumor as it moves). Because the CT imaging and target contouring methods differ depending on which respiratory management technique is used, each facility must develop its own optimal protocol. Practice guidelines for SBRT were published in 2010 by ASTRO (American Society for Radiation Oncology) and ACR (American College of Radiology).\u003c\/p\u003e\n\n\u003ch2 id=\"dose\"\u003eRadiation Doses Used in SBRT\u003c\/h2\u003e\n\n\u003cp\u003eThere is no single \"standard\" dose prescription for liver SBRT — and few large-scale reports or randomized phase III trials exist to definitively settle the question. The appropriate regimen depends on the size and location of the tumor and its relationship to nearby organs at risk. Across published studies, the dose for fractionated SBRT varies from \u003cstrong\u003e25 to 75 Gy in 3 to 6 fractions\u003c\/strong\u003e, with \u003cstrong\u003e3 fractions being the most common schedule\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eFor 3-fraction regimens, a key recommendation comes from Chang et al., who advised a \u003cstrong\u003etotal dose of at least 48 Gy\u003c\/strong\u003e to achieve sufficient local control (1-year local control greater than 90%). For single-fraction SBRT, several prospective trials have prescribed \u003cstrong\u003e14–30 Gy in one session\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eInterestingly, most studies so far have not adjusted the prescribed dose based on the primary cancer type (breast, colon, lung, etc.). However, some researchers, including Yamashita et al., have proposed that \u003cstrong\u003edose escalation for metastatic liver tumors\u003c\/strong\u003e may be reasonable — noting that metastatic lung tumors require higher doses because they are relatively less radiosensitive. In the future, dosing might become more individualized as differences in radiation sensitivity between cancer types become clearer.\u003c\/p\u003e\n\n\u003ch2 id=\"constraints\"\u003eProtecting Healthy Organs: Dose Constraints\u003c\/h2\u003e\n\n\u003cp\u003eBecause SBRT delivers very high doses of radiation, protecting the organs near the liver is critical. Scorsetti et al. published recommended dose constraints (safety limits) for organs at risk (OARs) during liver SBRT:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth\u003eOrgan\u003c\/th\u003e\n      \u003cth\u003eDose-Volume Limit\u003c\/th\u003e\n      \u003cth\u003eOther Conditions\u003c\/th\u003e\n    \u003c\/tr\u003e\n  \u003c\/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eHealthy liver\u003c\/td\u003e\n      \u003ctd\u003eReceiving less than 15 Gy: \u0026gt;700 cc\u003c\/td\u003e\n      \u003ctd\u003eHealthy liver volume \u0026gt;700 cc\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eSpinal cord\u003c\/td\u003e\n      \u003ctd\u003eD 0.1 cm³ \u0026lt; 18 Gy\u003c\/td\u003e\n      \u003ctd\u003eMaximum dose to 0.1 cc of the cord\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eKidneys (right + left)\u003c\/td\u003e\n      \u003ctd\u003eV15 Gy \u0026lt; 35%\u003c\/td\u003e\n      \u003ctd\u003eLess than 35% of kidney volume receives 15 Gy\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eStomach, duodenum, small bowel\u003c\/td\u003e\n      \u003ctd\u003eV21 Gy \u0026lt; 1%\u003c\/td\u003e\n      \u003ctd\u003eGross tumor volume (GTV) more than 8 mm from the organs at risk\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eHeart\u003c\/td\u003e\n      \u003ctd\u003eV30 Gy \u0026lt; 1%\u003c\/td\u003e\n      \u003ctd\u003eLess than 1% of heart volume receives 30 Gy\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n      \u003ctd\u003eRibs\u003c\/td\u003e\n      \u003ctd\u003eD30 cm³ \u0026lt; 30 Gy\u003c\/td\u003e\n      \u003ctd\u003eMaximum dose to 30 cc of rib volume less than 30 Gy\u003c\/td\u003e\n    \u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThese constraints have been used in clinical trials with slight variations, and several published reports provide helpful guidance for clinical teams planning liver SBRT.\u003c\/p\u003e\n\n\u003ch2 id=\"concomitant\"\u003eCombining SBRT with Systemic Therapy\u003c\/h2\u003e\n\n\u003cp\u003eAdding SBRT to systemic therapy could prolong survival, but the optimal sequence and timing of radiation and drug therapy for patients with oligometastatic breast cancer liver lesions is still being discussed. Reassuringly, \u003cstrong\u003eno studies have reported increased adverse events when systemic therapy and SBRT are combined\u003c\/strong\u003e. This means patients on chemotherapy, hormone therapy, or targeted therapy can likely safely undergo SBRT — an important consideration for integrating this treatment into a comprehensive care plan.\u003c\/p\u003e\n\n\u003ch2 id=\"results\"\u003eTreatment Results: What Studies Show\u003c\/h2\u003e\n\n\u003cp\u003eAn increasing number of retrospective and prospective studies have demonstrated the effectiveness of SBRT for liver metastases, including those originating from breast cancer. The reported results are impressive:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003e1-year local control rates range from 70% to 100%\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003e2-year local control rates range from 60% to 90%\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eMedian overall survival after liver SBRT ranges widely, from 10 to 48 months\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe variation between studies is thought to depend on differences in tumor volume, tumor histopathology (the specific cancer type), prior therapy, radiation dose, and fractionation regimen. Importantly, several reports looking at multiple primary cancer types have identified \u003cstrong\u003ebreast cancer origin as a favorable prognostic factor\u003c\/strong\u003e — meaning breast cancer liver metastases respond particularly well to SBRT compared to other cancers. Rusthoven and Mahadevan classified primary tumors into \"favorable\" and \"unfavorable\" groups based on survival outcomes, and breast cancer fell into the favorable group. Swaminath et al., analyzing 81 patients with 142 metastases, also reported that breast cancer subtype was one of the factors influencing time to local progression.\u003c\/p\u003e\n\n\u003cp\u003eHere is a summary of key studies on SBRT for liver metastases, including those specifically focused on breast cancer:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003cthead\u003e\n    \u003ctr\u003e\n      \u003cth\u003eStudy (Year)\u003c\/th\u003e\n      \u003cth\u003ePatients [Lesions]\u003c\/th\u003e\n      \u003cth\u003eBreast Cancer Patients\u003c\/th\u003e\n      \u003cth\u003eTumor Volume (Median, cm³)\u003c\/th\u003e\n      \u003cth\u003eFollow-up (Months)\u003c\/th\u003e\n      \u003cth\u003eRT Dose (Gy\/Fractions)\u003c\/th\u003e\n      \u003cth\u003eToxicity (Grade 3\/≥4)\u003c\/th\u003e\n      \u003cth\u003eMedian Survival (Months)\u003c\/th\u003e\n      \u003cth\u003eLocal Control (1y\/2y)\u003c\/th\u003e\n      \u003cth\u003eOverall Survival (1y\/2y)\u003c\/th\u003e\n    \u003c\/tr\u003e\n  \u003c\/thead\u003e\n  \u003ctbody\u003e\n    \u003ctr\u003e\n\u003ctd\u003eWulf (2006)\u003c\/td\u003e\n\u003ctd\u003e39 [51]\u003c\/td\u003e\n\u003ctd\u003e11\u003c\/td\u003e\n\u003ctd\u003eNA\u003c\/td\u003e\n\u003ctd\u003e15\u003c\/td\u003e\n\u003ctd\u003e26–37.5 Gy\/1–3 Fr\u003c\/td\u003e\n\u003ctd\u003e0\/0\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e92%\/66%\u003c\/td\u003e\n\u003ctd\u003e72%\/32%\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eLee (2009)\u003c\/td\u003e\n\u003ctd\u003e68 [143]\u003c\/td\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003ctd\u003e75.9\u003c\/td\u003e\n\u003ctd\u003e10.8\u003c\/td\u003e\n\u003ctd\u003e41.4 Gy\/6 Fr\u003c\/td\u003e\n\u003ctd\u003eAcute: 6 (9%)\/1 (1%); Late: 0\/0\u003c\/td\u003e\n\u003ctd\u003e17.6\u003c\/td\u003e\n\u003ctd\u003e79% (1y)\u003c\/td\u003e\n\u003ctd\u003e71% (1y)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eRusthoven (2009)\u003c\/td\u003e\n\u003ctd\u003e48 [63]\u003c\/td\u003e\n\u003ctd\u003eNA\u003c\/td\u003e\n\u003ctd\u003eDiameter 2.7 cm\u003c\/td\u003e\n\u003ctd\u003e16\u003c\/td\u003e\n\u003ctd\u003e36–60 Gy\/3 Fr\u003c\/td\u003e\n\u003ctd\u003e1 (2%)\u003c\/td\u003e\n\u003ctd\u003e20.5\u003c\/td\u003e\n\u003ctd\u003e92%\/95%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eFumagalli (2012)\u003c\/td\u003e\n\u003ctd\u003e90 [139]\u003c\/td\u003e\n\u003ctd\u003e8\u003c\/td\u003e\n\u003ctd\u003e28\u003c\/td\u003e\n\u003ctd\u003e17\u003c\/td\u003e\n\u003ctd\u003e27–60 Gy\/3–6 Fr\u003c\/td\u003e\n\u003ctd\u003e0\/0\u003c\/td\u003e\n\u003ctd\u003e70.0 (2y)\u003c\/td\u003e\n\u003ctd\u003e84.5%\/66.1%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eYuan (2014)\u003c\/td\u003e\n\u003ctd\u003e57 [80]\u003c\/td\u003e\n\u003ctd\u003e7\u003c\/td\u003e\n\u003ctd\u003e27.6\u003c\/td\u003e\n\u003ctd\u003e20.5\u003c\/td\u003e\n\u003ctd\u003e39–54 Gy\/3–7 Fr\u003c\/td\u003e\n\u003ctd\u003e0\/0\u003c\/td\u003e\n\u003ctd\u003e37.5\u003c\/td\u003e\n\u003ctd\u003e89.6%\/72.2%\u003c\/td\u003e\n\u003ctd\u003e94.4%\/89.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eYamashita (2014)\u003c\/td\u003e\n\u003ctd\u003e51\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003ctd\u003e26\u003c\/td\u003e\n\u003ctd\u003e475.5 days\u003c\/td\u003e\n\u003ctd\u003e30–60 Gy\/3–8 Fr\u003c\/td\u003e\n\u003ctd\u003e0\/0\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e64.2% (2y)\u003c\/td\u003e\n\u003ctd\u003e71.9% (2y)\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eScorsetti (2016)\u003c\/td\u003e\n\u003ctd\u003e33 [43]\u003c\/td\u003e\n\u003ctd\u003e33 (100%)\u003c\/td\u003e\n\u003ctd\u003e20\u003c\/td\u003e\n\u003ctd\u003e24\u003c\/td\u003e\n\u003ctd\u003e48–57 Gy\/3–4 Fr\u003c\/td\u003e\n\u003ctd\u003e0\/0\u003c\/td\u003e\n\u003ctd\u003e48\u003c\/td\u003e\n\u003ctd\u003e93%\/66%\u003c\/td\u003e\n\u003ctd\u003e98%\/90%\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eOnal (2018)\u003c\/td\u003e\n\u003ctd\u003e22 [29]\u003c\/td\u003e\n\u003ctd\u003e22 (100%)\u003c\/td\u003e\n\u003ctd\u003e16\u003c\/td\u003e\n\u003ctd\u003e16.0\u003c\/td\u003e\n\u003ctd\u003e54 Gy\/3 Fr\u003c\/td\u003e\n\u003ctd\u003eNA\/0\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e100%\/88%\u003c\/td\u003e\n\u003ctd\u003e85%\/57%\u003c\/td\u003e\n\u003c\/tr\u003e\n    \u003ctr\u003e\n\u003ctd\u003eMahadevan (2018)\u003c\/td\u003e\n\u003ctd\u003e427 [568]\u003c\/td\u003e\n\u003ctd\u003e42\u003c\/td\u003e\n\u003ctd\u003e40\u003c\/td\u003e\n\u003ctd\u003e14\u003c\/td\u003e\n\u003ctd\u003e45 [12–60] Gy\/3 Fr\u003c\/td\u003e\n\u003ctd\u003e0\/0\u003c\/td\u003e\n\u003ctd\u003e22 (median)\u003c\/td\u003e\n\u003ctd\u003e52 months (median LC)\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n  \u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eTwo studies focused exclusively on breast cancer liver metastases deserve special attention. \u003cstrong\u003eOnal et al.\u003c\/strong\u003e combined liver SBRT with systemic treatment in 22 patients with 29 breast cancer liver metastases, reporting excellent results: 1- and 2-year overall survival rates of 85% and 57%, and 1- and 2-year local control rates of 100% and 88%, respectively. \u003cstrong\u003eScorsetti et al.\u003c\/strong\u003e treated lung or liver oligometastases from breast cancer with SBRT and achieved 1- and 2-year overall survival rates of 93% and 66%, with 1- and 2-year local control rates of 100% and 88%. The authors of these studies concluded that \u003cstrong\u003eSBRT may be an effective and safe treatment option in selected patients with BCLM\u003c\/strong\u003e. Chang et al. further confirmed that higher prescription doses produce better local control, recommending a total dose greater than 48 Gy for 3-fraction regimens.\u003c\/p\u003e\n\n\u003ch2 id=\"predictors\"\u003ePredictors of Success: Who Benefits Most?\u003c\/h2\u003e\n\n\u003cp\u003eNot all patients respond equally to SBRT, and researchers have identified several prognostic factors associated with better outcomes. The most consistent favorable predictors of local control are:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTumor size\u003c\/strong\u003e — Smaller tumors respond better. A diameter of 30 or 40 mm is frequently used as the cut-off value in studies. Yamashita et al. found that maximum tumor diameter \u0026gt;30 mm versus ≤30 mm was the only significant factor for local control. Mahadevan et al. reported that smaller tumor volumes (\u0026lt;40 cm³) are associated with improved local control and overall survival.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePrescription dose\u003c\/strong\u003e — Higher doses produce better outcomes. Chang et al. found that total dose (P=0.0015), dose per fraction (P=0.003), and biologically effective dose (BED) (P=0.004) all correlated with local control. Mahadevan and Yuan both reported that a \u003cstrong\u003eBED ≥100 Gy\u003c\/strong\u003e was associated with improved local control (2-year local control rates of 77.2% vs. 59.6%). McCammon et al. demonstrated significant improvement with increasing dose: 3-year local control rates were \u003cstrong\u003e89.3% for lesions receiving 54–60 Gy, 59% for 36–53.9 Gy, and only 8.1% for less than 36 Gy\u003c\/strong\u003e (P\u0026lt;0.01).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHistology (cancer type)\u003c\/strong\u003e — As noted, breast cancer is a favorable histology for SBRT of liver metastases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAdditional factors associated with favorable overall survival include good performance status, solitary metastasis (only one metastatic spot), metachronous metastases (cancer spread that occurred later, rather than at initial diagnosis), and receiving chemotherapy before SBRT.\u003c\/p\u003e\n\n\u003ch2 id=\"toxicity\"\u003eSide Effects and Toxicity: How Safe Is SBRT?\u003c\/h2\u003e\n\n\u003cp\u003eSevere toxicity from liver radiation is rare — especially with SBRT. According to Ihnát et al., \u003cstrong\u003egrade 3 side effects occur in less than 5% of SBRT cases\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAcute (short-term) side effects:\u003c\/strong\u003e The most common are grade 1–2 gastrointestinal symptoms — nausea, vomiting, abdominal pain, and peptic ulcers — experienced by \u003cstrong\u003e10–30% of patients\u003c\/strong\u003e. Depending on the treatment location, other less frequent side effects can include chest wall pain, dermatitis (skin irritation), pneumonia, and renal (kidney) dysfunction.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLate side effects:\u003c\/strong\u003e Late adverse events include gastrointestinal ulcers and perforations, bile duct stenosis (narrowing of bile ducts), pulmonary fibrosis (lung scarring), and renal fibrosis (kidney scarring). Fortunately, serious cases of any of these are rarely reported.\u003c\/p\u003e\n\n\u003ch2 id=\"rild\"\u003eRadiation-Induced Liver Disease: A Key Concern\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eRadiation-induced liver disease (RILD)\u003c\/strong\u003e is an acute reaction that occurs between \u003cstrong\u003e2 weeks and 4 months after radiation therapy\u003c\/strong\u003e. It is characterized by \u003cstrong\u003eanicteric ascites\u003c\/strong\u003e (fluid buildup in the abdomen without yellowing of the skin\/eyes), along with elevation of \u003cstrong\u003ealkaline phosphatase\u003c\/strong\u003e and \u003cstrong\u003eliver transaminases\u003c\/strong\u003e (enzymes that signal liver damage). In severe cases, RILD can result in liver failure and death.\u003c\/p\u003e\n\n\u003cp\u003eOlder studies by Emami et al. reported the radiation doses that carry a 5% risk of RILD as \u003cstrong\u003e50 Gy, 35 Gy, and 30 Gy\u003c\/strong\u003e for one-third, two-thirds, and the whole liver, respectively. These criteria are still widely used. However, Lawrence et al. later argued that with proper restriction of the irradiated area of normal liver, it was possible to deliver \u003cstrong\u003emore than 90 Gy\u003c\/strong\u003e without causing RILD. Dawson's research on 204 patients showed the 5% risk dose for RILD was \u003cstrong\u003e54 Gy when two-thirds of the liver was irradiated, and 100 Gy when only one-third was irradiated\u003c\/strong\u003e — substantially higher than earlier estimates.\u003c\/p\u003e\n\n\u003cp\u003eThe key takeaway: although RILD is the most limiting side effect of liver irradiation, its occurrence depends heavily on how much healthy liver tissue is exposed. It can be prevented by carefully limiting the radiation dose to normal liver tissue. After Méndez Romero et al. reported two cases of RILD after SBRT, very few additional cases have been described in liver SBRT studies. The recent very low incidence of RILD is likely a direct result of the extreme accuracy of radiation delivery achieved with SBRT.\u003c\/p\u003e\n\n\u003ch2 id=\"conclusions\"\u003eConclusions: Where SBRT Stands Today\u003c\/h2\u003e\n\n\u003cp\u003ePublished data on SBRT for liver oligometastases demonstrate \u003cstrong\u003epromising results, particularly in terms of local control and safety\u003c\/strong\u003e — even though most patients treated in these studies had been deemed inoperable before treatment. The authors of this review conclude that SBRT can be considered a \u003cstrong\u003esafe and feasible alternative to surgical resection and ablation in selected patients with breast cancer liver metastases\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eFor patients, this means that a diagnosis of breast cancer liver metastases no longer automatically rules out effective local treatment. SBRT offers a non-invasive option with excellent tumor control, a low risk of serious side effects, and meaningful survival outcomes.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of the Current Evidence\u003c\/h2\u003e\n\n\u003cp\u003eThe authors are candid about the limitations of the existing research. The number of patients in studies focusing specifically on breast cancer liver metastases is small, and observation periods are relatively short. The patient selection criteria and the optimal dose and fractionation for liver SBRT are \u003cstrong\u003estill under investigation\u003c\/strong\u003e. There is currently \u003cstrong\u003eno randomized phase III trial data\u003c\/strong\u003e for SBRT in liver metastases. The authors state clearly that prospective randomized trials and further studies are required to define the appropriate targets and methods for SBRT and to establish its definitive role in BCLM.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this review, here are some practical points for patients with breast cancer liver metastases — and for anyone exploring treatment options:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about SBRT if surgery isn't an option.\u003c\/strong\u003e If you have a limited number of liver metastases (5 or fewer, each ≤6 cm) and are not a candidate for surgery or ablation, SBRT is a well-supported alternative that offers high local control rates with minimal side effects.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow that breast cancer responds well to SBRT.\u003c\/strong\u003e Multiple studies classify breast cancer as a favorable tumor type for this treatment. Don't assume your cancer is inherently \"hard to treat\" in the liver.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExpect a brief, non-invasive treatment course.\u003c\/strong\u003e Most SBRT regimens involve 3 sessions, though some range from 1 to 8 sessions depending on the facility and tumor specifics. There's no cutting and typically no hospital stay.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about your liver function and tumor location.\u003c\/strong\u003e Good candidates typically have Child-Pugh A liver function, enough healthy liver volume (\u0026gt;700–1,000 mL that can be spared from radiation), and tumors located at least 8 mm away from sensitive organs.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eContinue your systemic therapy.\u003c\/strong\u003e SBRT is intended to complement — not replace — chemotherapy, hormone therapy, or targeted therapy. Research so far shows no increased side effects when combining SBRT with systemic treatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExpect mild, manageable side effects.\u003c\/strong\u003e Nausea, vomiting, or abdominal discomfort occur in 10–30% of patients but are typically mild (grade 1–2). Serious side effects happen in fewer than 5% of cases.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss dosing with your radiation oncologist.\u003c\/strong\u003e For 3-fraction plans, a total dose of at least 48 Gy (or a biologically effective dose of ≥100 Gy) is associated with the best local control.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is SBRT and how does it treat breast cancer that has spread to the liver?\u003c\/h3\u003e\n\u003cp\u003eStereotactic body radiotherapy (SBRT) delivers precise, high-dose radiation to tumors in a few sessions, usually 1 to 6, while sparing surrounding healthy liver. It is non-invasive and offers an alternative to surgery or ablation. For breast cancer liver metastases, studies report excellent local control with minimal serious side effects.\u003c\/p\u003e\n\u003ch3\u003eAm I eligible for SBRT for liver metastases from breast cancer?\u003c\/h3\u003e\n\u003cp\u003eTypical eligibility in studies includes up to 5 liver metastases, each no larger than 6 cm, controlled or absent cancer outside the liver, good performance status, and adequate liver function, often Child-Pugh class A with more than 700–1000 mL of healthy liver that can be spared. Tumors should sit at least 8 mm from sensitive organs.\u003c\/p\u003e\n\u003ch3\u003eHow is SBRT delivered? How many treatments are needed?\u003c\/h3\u003e\n\u003cp\u003eBefore each session, imaging like CT and MRI is used to target the tumor precisely. Techniques reduce motion from breathing, such as abdominal compression or tracking the tumor. Most SBRT regimens involve 3 sessions, though some range from 1 to 8, depending on the facility and tumor specifics.\u003c\/p\u003e\n\u003ch3\u003eWhat side effects can I expect from SBRT for liver metastases?\u003c\/h3\u003e\n\u003cp\u003eMild gastrointestinal symptoms like nausea, vomiting, or abdominal discomfort occur in 10–30% of patients, typically grade 1–2. Serious side effects happen in fewer than 5% of cases. A rare but important risk is radiation-induced liver disease, which can be prevented by limiting healthy liver exposure.\u003c\/p\u003e\n\u003ch3\u003eHow well does SBRT work for breast cancer that has spread to the liver?\u003c\/h3\u003e\n\u003cp\u003eReported 1-year local control rates range from 70% to 100%, and 2-year rates from 60% to 90%. Studies focusing on breast cancer liver metastases, such as a trial of 22 patients, showed 1- and 2-year local control of 100% and 88%. Breast cancer is considered a favorable type for SBRT.\u003c\/p\u003e\n\u003ch3\u003eCan I continue chemotherapy or hormone therapy during SBRT?\u003c\/h3\u003e\n\u003cp\u003eYes. SBRT is intended to complement, not replace, systemic therapy. No studies have reported increased side effects when combining SBRT with chemotherapy, hormone therapy, or targeted therapy. The optimal timing and sequence are still being discussed, so ask your oncologist about your specific treatment plan.\u003c\/p\u003e\n\u003ch3\u003eWhat radiation dose should I receive for breast cancer liver metastases?\u003c\/h3\u003e\n\u003cp\u003eNo single standard dose exists. For 3-fraction SBRT, a total dose of at least 48 Gy is recommended to achieve more than 90% 1-year local control. Biologically effective dose of at least 100 Gy has also been linked to better local control. Your radiation oncologist will tailor dosing to tumor size, location, and nearby organs.\u003c\/p\u003e\n\u003ch3\u003eShould I get a second opinion to find out if I really need surgery for breast cancer liver metastases, or is SBRT an alternative option for me?\u003c\/h3\u003e\n\u003cp\u003eFor breast cancer that has spread only to the liver, surgery has been the traditional first choice, but only 10–30% of patients are eligible. In selected patients with up to five liver metastases no larger than 6 cm, SBRT offers a non-invasive alternative, with one-year local control rates of 70–100% and serious side effects in fewer than 5% of patients. A second opinion can help clarify whether surgery is truly necessary or whether SBRT is suitable for your specific liver function and tumor location. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003eThis patient-friendly article is based on the following peer-reviewed research:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOriginal Article Title:\u003c\/strong\u003e Stereotactic body radiotherapy (SBRT) for oligo-metastatic liver metastases from breast cancer\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47541991047324,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/de\/products\/radiation-without-surgery-how-sbrt-is-changing-treatment-for-breast-cancer-liver-metastases","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}